Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Considerations in the Management of Parkinsonism
Neurol 28:5, Fahn,S.,et al, 1978
Catecholamines & Neurologic Diseases
NEJM 293:274, Moskowitz,M.A.,et al, 1975
A 6-Year-Old Girl with Progressive Toe Walking
Neurol 98:e769-e773, Libdeh, A.A. & Ibrahim, A., 2022
A 56-year-old Man with Cognitive Impairment and Difficulty Tying his Necktie
Neurol 85:e116-e122, Baker, J.M.,et al, 2015
Long-Term Effectivenss of Dopamine Agonists and Monoamine Oxidase B Inhibitors Compared with Levodopa as Initial Treatment for Parkinsons Disease (PD MED): A Large, Open-Label, Pragmatic Randomised Trial
Lancet 383: Doi: 10.1016/S0140-6736, PD MED Collaborative Group, 2014
Othello Syndrome in Parkinson Disease Patients Without Dementia
The Neurologist 15:34-36, Cannas,A.,et al, 2009
Long-Term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
Arch Neurol 66:563-570, Parkinson Sutdy Group CALM Cohort Investigators, 2009
Progressive Supranuclear Palsy: A Current Review
The Neurologist 14:79-88, Lubarsky,M. &Juncos,J.L., 2008
Fourteen-Year Final Report of the Randomized PDRG-UK Trial Comparing Three Treatments in PD
Neurol 71:474-480.470, Katzenschlager,R.,et al., 2008
Functional Abnormalities Underlying Pathological Gambling in Parkinson Disease
Arch Neurol 65:1604-1611, Cilia,R.,et al, 2008
Levodopa for the Treatment of Parkinsons Disease
NEJM 359:2468-2476, LeWitt,P.A., 2008
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
Ropinirole 24-Hour Prolonged Release: Randomized, Controlled Study in Advanced Parkinson Disease
Neurol 68:1108-1115, Pahwa,R.,et al, 2007
Vascular Parkinsonism and Dementia in a CADASIL Case with Intact Nigrostriatal Dopaminergic System
Akt Neurol 33: Suppl, Wegner,F.,et al, 2006
The Role of Levodopa in the Management of Dementia With Lewy Bodies
JNNP 76:1200-1203, Moloy,S.,et al, 2005
Diagnosis and Initial Management of Parkinsons Disease
NEJM 353:1021-1027, Nutt,J.G.&Wooten,G.F., 2005
Levodopa and the Progression of Parkinson's Disease
NEJM 351:2498-2508, The Parkinson Study Group, 2004
Restless Legs Syndrome
NEJM 348:2103-2109, Earley,C.J., 2003
Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression
JAMA 287:1653-1661, Parkinson Study Group, 2002
Ten-year Follow-up of Three Different Initial Treatments in De-novo PD
Neurol 57:1687-1694, Lees,A.J.,et al, 2001
A Five-Year Study of the Incidence of Dyskinesia in Patients With Early Parkinson's Disease who were Treated with Ropinirole or Levodopa
NEJM 342:1484-1491, Rascol,O.,et al, 2000
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease
JAMA 284:1931-1938,1971, Parkinson Study Group, 2000
Managing the Neuropsychiatric Symptoms of Parkinson's Disease
Neurol 50:S33-S38, Lieberman,A., 1998
Parkinson's Disease
NEJM 339:1044-1053,1130-1143, Lang,A.E.&Lozano,A.M., 1998
Subcotical Arteriosclerotic Encephalopathy (Binswangers Disease)
, Ghika,J. &Bogousslavsky, J., 1998
Sympathetic Cardioneuropathy in Dysautonomias
NEJM 336:696-702, 7211997., Goldstein,D.S.,et al, 1997
Cabergoline Treatment of Early Parkinson's Disease:First Yr of Trtm Comparison of Cabergoline & Levodopa
Neurol 48:363-368, Rinne,U.K.,et al, 1997
Restless Legs Syndrome:Clinicoetiologic Correlates
Neurol 47:1435-1441, Ondo,W.&Jankovic,J., 1996
Nonmotor Fluctuations in Patients with Parkinson's Disease
Neurol 47:1180-1183, Hillen,M.E.&Sage,J.I., 1996
Drug Treatment of Parkinson's Disease
BMJ 310:575-579, Quinn,N., 1995
Multiple System Atrophy presenting as Parkinsonism:Clinical Features and Diagnostic Criteria
JNNP 59:144-151, Albanese,A.,et al, 1995
Dopa-Responsive Dystonia:Pathological and Biochemical Observations in a Case
Ann Neurol 35:396-402, 3811994., Rajput,A.H.,et al, 1994
A Multicenter Double-Blind Placebo-Controlled Trial of Pergolide as an Adjunct to Sinemet in Parkinson's Disease
Movement Disorders, 9:40-471994., Olanow,C.W.,et al, 1994
Comparisons of Therapeutic Effects of Levodopa
Levodopa & Selegiline, & Bromocriptine in Pts with Early, Mild Parkinson's, Parkinson's Res Grp in U, , BMJ 372,1993., 1993
The Spectrum of Levodopa-Related Fluctuations in Parkinson's Disease
Neurol 43:1459-1464, Riley,D.E.&Lang,A.E., 1993
Levodopa-Nonresponsive Lewy Body Parkinsonism:Clinicopathologic Study of Two Cases
Neurol 42:1323-1327, Mark,M.H.,et al, 1992
Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 47:1085-1087, Wolters,W.Ch.,et al, 1992
Dopa-Responsive Dystonia:Long-Term Treatment Response and Prognosis
Neurol 41:174-181, Nygaard,T.G.,et al, 1991
Neuroleptic Malignant Synd in Parkinson's after Withdrawal or Alteration of Dopaminergic Therapy
Arch Int Med 151:794-796, Keyser,D.L.&Rodnitzky,R.L., 1991
Lisuride, A Dopamine Agonist in the Treatment of Early Parkinson's Disease
Neurol 39:336-339, Rinne,U.K., 1989
Diffuse Lewy Body Disease:Clinical Features in 15 Cases
JNNP 52:709-717, Byrne,E.J., 1989
International Symposium on Early Dopamine Agonist Therapy of Parkinson's Disease
Arch Neurol 45:204-208, Kurlan,R., 1988
Early Combination of Bromocriptine & Levodopa in the Treatment of Parkinson's Disease:A 5-Year Follow-up
Neurol 37:826-828, Rinne,U.K., 1987
Dystonia-Parkinson Syndrome:Differential Effects of Levodopa and Dopamine Agonists
Clin Neuropharmacol 9:298-302, Klawans,H.L.&Paleologos,N., 1986
Low Dosages of Bromocriptine Added to Levodopa in Parkinson's Disease
Neurol 35:199-206, Maier,M.M.,et al, 1985
Bromocriptine in Parkinson Disease:Further Studies
Neurol 29:363-369, Lieberman,A.N.,et al, 1979